DermTech, Inc. (DMTK)

NASDAQ: DMTK · IEX Real-Time Price · USD
6.80
-0.50 (-6.85%)
May 18, 2022 1:05 PM EDT - Market open
Market Cap203.60M
Revenue (ttm)13.03M
Net Income (ttm)-93.38M
Shares Out29.94M
EPS (ttm)-2.71
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume506,104
Open7.03
Previous Close7.30
Day's Range6.62 - 7.10
52-Week Range6.39 - 48.32
Beta0.94
AnalystsBuy
Price Target33.49 (+392.5%)
Earnings DateMay 3, 2022

About DMTK

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 i...

IndustryBiotechnology
Employees255
Stock ExchangeNASDAQ
Ticker SymbolDMTK
Full Company Profile

Financial Performance

In 2021, DermTech's revenue was $11.84 million, an increase of 101.16% compared to the previous year's $5.89 million. Losses were -$78.34 million, 114.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for DMTK stock is "Buy." The 12-month stock price forecast is 33.49, which is an increase of 392.50% from the latest price.

Price Target
$33.49
(392.50% upside)
Analyst Consensus: Buy
Stock Forecasts

News

DermTech Reinforces Longstanding Mission to Help Reduce Melanoma Deaths, Aligning with the Biden Administration's Ren...

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its co...

1 week ago - Business Wire

DermTech Kicks Off Second Annual #Stickit2Melanoma Campaign, Raising Awareness for Melanoma and the Importance of Ski...

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the re...

1 week ago - Business Wire

DermTech, Inc. (DMTK) Reports Q1 Loss, Misses Revenue Estimates

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -18.82% and 1.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

DermTech Reports First-Quarter 2022 Financial Results; Company Affirms Full-Year 2022 Outlook

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its fir...

2 weeks ago - Business Wire

DermTech Announces Publication of New GvHD Clinical Research Conducted in Collaboration with Memorial Sloan Kettering...

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the pu...

2 weeks ago - Business Wire

DermTech Expands Telehealth Application, DermTech Connect, Across 44 States

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the ex...

3 weeks ago - Business Wire

DermTech to Showcase DermTech Stratum, an Expanded Translational Medicine Service Offering, at San Diego's Inaugural ...

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that i...

3 weeks ago - Business Wire

DermTech Announces Release Date for First-Quarter 2022 Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conference...

1 month ago - Business Wire

CasperLabs Appoints Michael Dobak as Company's First Chief Marketing Officer to Drive Business Adoption of Blockchain...

ZUG, Switzerland & NEW YORK--(BUSINESS WIRE)--CasperLabs, a leading blockchain software company for the enterprise market, is pleased to announce that Michael Dobak has been appointed to the position of...

1 month ago - Business Wire

DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the grant to one new em...

1 month ago - Business Wire

DermTech Study, “Cost-Benefit Analysis of the Pigmented Lesion Assay When Introduced into the Visual Assessment / His...

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that S...

2 months ago - Business Wire

DermTech, Inc. (DMTK) Reports Q4 Loss, Lags Revenue Estimates

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -20.55% and 5.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

DermTech Reports Fourth Quarter and Full Year 2021 Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported financial results as of ...

2 months ago - Business Wire

DermTech Management to Present at Upcoming Investor Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management wil...

2 months ago - Business Wire

DermTech Welcomes Adelle Walker as Vice President of Consumer Products

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the ad...

2 months ago - Business Wire

DermTech to Announce Fourth Quarter and Full-Year Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it plans to releas...

3 months ago - Business Wire

DermTech Management to Participate in Upcoming Investor Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management wil...

3 months ago - Business Wire

Should You Sell DermTech and GoodRx Stocks Right Now?

It may depend on the underlying premise of what the company is all about.

Other symbols:GDRX
3 months ago - The Motley Fool

Want $1 Million? Buy and Hold These 2 Stocks for the Next Decade

These two stocks could provide life-changing returns in 10 years.

Other symbols:DOCS
4 months ago - The Motley Fool

BioIQ and DermTech Enter into an Agreement to Add Non-invasive DermTech Melanoma Test to BioIQ's Health Testing Solut...

ATLANTA and LA JOLLA, Calif., Dec. 15, 2021 /PRNewswire/ -- BioIQ, Inc., ("BioIQ") an analytics-driven population health and testing platform company for top employers, health plans, and government agen...

5 months ago - PRNewsWire

Why DermTech Still Has Ten-Bagger Potential

Skin-cancer detection could lead to big returns for this stock.

5 months ago - The Motley Fool

DermTech Unveils DermTech Stratum, an Expanded Translational Medicine Service Offering for Non-invasive Biomarker Ana...

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the ex...

5 months ago - Business Wire

This Is the Main Problem With DermTech's Q3 Results

Nothing major changed for the skin genomics company in Q3.

5 months ago - The Motley Fool

DermTech Presents Precision Approaches to Personalized Dermatology at 2021 Dermatology Drug Development Summit

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its session presentatio...

5 months ago - Business Wire

Got $50? 3 Roughed-Up Growth Stocks Set to Soar

These stocks have grown quarterly sales 34%, 43%, and 140% year over year.

Other symbols:FIGSPINS
6 months ago - The Motley Fool